Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Finished Goods (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Finished Goods over the past 3 years, most recently at $2.1 million for Q4 2025.

  • Quarterly results put Finished Goods at $2.1 million for Q4 2025, down 58.29% from a year ago — trailing twelve months through Dec 2025 was $2.1 million (down 58.29% YoY), and the annual figure for FY2025 was $2.1 million, down 58.29%.
  • Finished Goods for Q4 2025 was $2.1 million at Tonix Pharmaceuticals Holding, up from $1.8 million in the prior quarter.
  • Over the last five years, Finished Goods for TNXP hit a ceiling of $7.5 million in Q4 2023 and a floor of $1.8 million in Q3 2025.
  • Median Finished Goods over the past 3 years was $2.6 million (2024), compared with a mean of $3.8 million.
  • Biggest five-year swings in Finished Goods: plummeted 31.58% in 2024 and later plummeted 58.29% in 2025.
  • Tonix Pharmaceuticals Holding's Finished Goods stood at $7.5 million in 2023, then crashed by 31.58% to $5.1 million in 2024, then plummeted by 58.29% to $2.1 million in 2025.
  • The last three reported values for Finished Goods were $2.1 million (Q4 2025), $1.8 million (Q3 2025), and $2.4 million (Q2 2025) per Business Quant data.